Source:http://linkedlifedata.com/resource/pubmed/id/16755570
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2006-6-12
|
| pubmed:abstractText |
Conventional treatment of mantle cell lymphoma (MCL) yields modest responses and short remissions. We report 30 hematopoietic stem cell transplants (HSCT) for MCL: 13 autologous, 10 allogeneic myeloablative, and 7 nonablative. After a median 1.2 years from diagnosis (range 0.5 to 4.7) and a median of 2 pre-HSCT chemotherapeutic regimens (range 1 to 5), their median age at HSCT was 52 years (range 37 to 67). Eleven patients (41%) were in first remission, 11 (41%) were in second remission, and 7 (25%) had resistant disease. Four died early. Nineteen achieved CR (83%) and 4 PR (17%). With median 2.7 years of follow-up, 5-year overall survival (OS) was 42% (95% CI 11-73%) after autologous versus allogeneic at 49% (95% CI 22-76%). Five-year progression-free survival (PFS) was 31% (95% CI 3-59%) and 50% (95% CI 24-76%) for autologous and allogeneic HSCT, respectively. Fourteen died: 3 from sepsis, 1 acute GVHD, 10 MCL. No autologous transplant-related deaths occurred. Allogeneic transplant-related mortality was 29% (95% CI 6-52%) at 1 and 5 years. HSCT for MCL can yield extended disease control and long-term survival.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0361-8609
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
81
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
519-24
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16755570-Adult,
pubmed-meshheading:16755570-Aged,
pubmed-meshheading:16755570-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16755570-Disease-Free Survival,
pubmed-meshheading:16755570-Drug Resistance, Neoplasm,
pubmed-meshheading:16755570-Female,
pubmed-meshheading:16755570-Follow-Up Studies,
pubmed-meshheading:16755570-Graft vs Host Disease,
pubmed-meshheading:16755570-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16755570-Humans,
pubmed-meshheading:16755570-Lymphoma, Mantle-Cell,
pubmed-meshheading:16755570-Male,
pubmed-meshheading:16755570-Middle Aged,
pubmed-meshheading:16755570-Remission Induction,
pubmed-meshheading:16755570-Retrospective Studies,
pubmed-meshheading:16755570-Sepsis,
pubmed-meshheading:16755570-Time Factors,
pubmed-meshheading:16755570-Transplantation, Autologous,
pubmed-meshheading:16755570-Transplantation, Homologous,
pubmed-meshheading:16755570-Transplantation Conditioning
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma.
|
| pubmed:affiliation |
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|